|
Xencor, Inc. (XNCR) Évaluation DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Xencor, Inc. (XNCR) Bundle
Découvrez la vraie valeur de Xencor, Inc. (XNCR) avec notre calculatrice DCF de qualité professionnelle! Ajustez les hypothèses clés, explorez divers scénarios et examinez comment les changements affectent la valorisation de Xencor, Inc. (XNCR) - le tout dans un seul modèle Excel.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 122.7 | 275.1 | 164.6 | 168.3 | 110.5 | 118.2 | 126.4 | 135.1 | 144.5 | 154.5 |
| Revenue Growth, % | 0 | 124.23 | -40.18 | 2.28 | -34.36 | 6.94 | 6.94 | 6.94 | 6.94 | 6.94 |
| EBITDA | -71.0 | 51.3 | -72.2 | -125.9 | -186.2 | -60.9 | -65.2 | -69.7 | -74.5 | -79.7 |
| EBITDA, % | -57.87 | 18.63 | -43.85 | -74.77 | -168.49 | -51.57 | -51.57 | -51.57 | -51.57 | -51.57 |
| Depreciation | 5.8 | 7.5 | 8.8 | 11.5 | 12.1 | 7.2 | 7.7 | 8.3 | 8.8 | 9.4 |
| Depreciation, % | 4.72 | 2.72 | 5.35 | 6.83 | 10.96 | 6.12 | 6.12 | 6.12 | 6.12 | 6.12 |
| EBIT | -76.8 | 43.8 | -81.0 | -137.4 | -198.3 | -65.6 | -70.1 | -75.0 | -80.2 | -85.7 |
| EBIT, % | -62.59 | 15.91 | -49.19 | -81.6 | -179.45 | -55.5 | -55.5 | -55.5 | -55.5 | -55.5 |
| Total Cash | 603.0 | 334.1 | 623.1 | 593.7 | 449.8 | 118.2 | 126.4 | 135.1 | 144.5 | 154.5 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 23.9 | 66.4 | 29.0 | 11.3 | 60.8 | 29.1 | 31.1 | 33.2 | 35.6 | 38.0 |
| Account Receivables, % | 19.51 | 24.13 | 17.62 | 6.71 | 55.07 | 24.61 | 24.61 | 24.61 | 24.61 | 24.61 |
| Inventories | .0 | -36.9 | .0 | .0 | .0 | -3.2 | -3.4 | -3.6 | -3.9 | -4.1 |
| Inventories, % | 0 | -13.4 | 0.000000608 | 0 | 0 | -2.68 | -2.68 | -2.68 | -2.68 | -2.68 |
| Accounts Payable | 9.0 | 14.0 | 10.1 | 13.9 | 16.8 | 9.9 | 10.6 | 11.3 | 12.1 | 13.0 |
| Accounts Payable, % | 7.3 | 5.09 | 6.13 | 8.27 | 15.17 | 8.39 | 8.39 | 8.39 | 8.39 | 8.39 |
| Capital Expenditure | -13.8 | -16.0 | -43.4 | -21.3 | -6.1 | -14.5 | -15.6 | -16.6 | -17.8 | -19.0 |
| Capital Expenditure, % | -11.22 | -5.81 | -26.37 | -12.62 | -5.52 | -12.31 | -12.31 | -12.31 | -12.31 | -12.31 |
| Tax Rate, % | 0.98117 | 0.98117 | 0.98117 | 0.98117 | 0.98117 | 0.98117 | 0.98117 | 0.98117 | 0.98117 | 0.98117 |
| EBITAT | -70.4 | 43.8 | -82.0 | -143.8 | -196.3 | -64.3 | -68.8 | -73.6 | -78.7 | -84.1 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -93.3 | 34.7 | -120.0 | -132.0 | -237.0 | -43.6 | -77.7 | -83.1 | -88.9 | -95.1 |
| WACC, % | 10.21 | 10.49 | 10.49 | 10.49 | 10.46 | 10.43 | 10.43 | 10.43 | 10.43 | 10.43 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -282.6 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -97 | |||||||||
| Terminal Value | -1,151 | |||||||||
| Present Terminal Value | -701 | |||||||||
| Enterprise Value | -983 | |||||||||
| Net Debt | 27 | |||||||||
| Equity Value | -1,011 | |||||||||
| Diluted Shares Outstanding, MM | 65 | |||||||||
| Equity Value Per Share | -15.54 |
What You Will Get
- Pre-Filled Financial Model: Xencor's actual data allows for accurate DCF valuation.
- Full Forecast Control: Modify revenue growth, profit margins, WACC, and other essential drivers.
- Instant Calculations: Automatic updates provide real-time results as you make adjustments.
- Investor-Ready Template: A polished Excel file crafted for high-quality valuation purposes.
- Customizable and Reusable: Designed for versatility, enabling repeated use for in-depth forecasts.
Key Features
- Pre-Loaded Data: Xencor, Inc.'s historical financial statements and pre-filled forecasts.
- Fully Adjustable Inputs: Modify WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Instant Results: Observe Xencor, Inc.'s intrinsic value recalculating in real time.
- Clear Visual Outputs: Dashboard charts present valuation results and essential metrics.
- Built for Accuracy: A professional tool designed for analysts, investors, and finance professionals.
How It Works
- Step 1: Download the prebuilt Excel template featuring Xencor, Inc. (XNCR) data.
- Step 2: Navigate through the pre-filled sheets to grasp the essential metrics.
- Step 3: Adjust forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly see the recalculated results, including Xencor, Inc. (XNCR)'s intrinsic value.
- Step 5: Make well-informed investment decisions or create reports based on the outputs.
Why Choose This Calculator for Xencor, Inc. (XNCR)?
- Designed for Experts: A sophisticated tool utilized by financial analysts, CFOs, and consultants.
- Accurate Financials: Xencor's historical and projected financial data preloaded for precision.
- Flexible Scenario Analysis: Effortlessly test various forecasts and assumptions.
- Comprehensive Outputs: Automatically computes intrinsic value, NPV, and essential metrics.
- User-Friendly: Step-by-step guidance to navigate through the calculations.
Who Should Use This Product?
- Investors: Evaluate Xencor, Inc.'s (XNCR) market performance before making investment decisions.
- CFOs and Financial Analysts: Optimize valuation methodologies and assess financial forecasts for Xencor, Inc. (XNCR).
- Startup Founders: Discover how biotech companies like Xencor, Inc. (XNCR) are valued in the market.
- Consultants: Provide detailed valuation analyses and reports for clients interested in Xencor, Inc. (XNCR).
- Students and Educators: Utilize case studies from Xencor, Inc. (XNCR) to teach and practice valuation strategies.
What the Template Contains
- Pre-Filled Data: Includes Xencor, Inc.'s historical financials and forecasts.
- Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
- Key Financial Ratios: Analyze Xencor, Inc.'s profitability, efficiency, and leverage.
- Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
- Clear Dashboard: Charts and tables summarizing key valuation results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.